Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.

Our first product, lixivaptan, is in Phase 2 development for the treatment of polycystic kidney disease (PKD).  PKD is one of the most common, life-threatening genetic diseases.  PKD causes numerous fluid-filled cysts to grow in both kidneys.  It is a life-limiting, chronic and progressive disease. PKD is the 4th leading cause of kidney failure and carries a significant financial and emotional burden, affecting entire families.

There is no cure for PKD.  We are developing lixivaptan to address the continuing unmet needs of patients, as a safe and effective agent to be used chronically to prevent the progression of PKD.

We closed a Series A venture round during the third quarter of 2016, allowing us to acquire lixivaptan and begin building our management team, which is supplemented with an extensive network of key consultants and service providers.

Management Team
Lorenzo Pellegrini, Ph.D.
Lorenzo is the Founder and Chief Executive Officer of Palladio Biosciences. Prior to founding Palladio, Lorenzo was a partner at Care Capital, a leading venture capital firm investing in drug development companies. During his twelve-year tenure at Care Capital, Lorenzo co-founded and served on the board of several portfolio companies, including Minerva Neurosciences (NASDAQ: NERV), Biocritica, and Sentinella Pharmaceuticals, among others. He also led the firm’s investments in Elevation Pharmaceuticals (acquired by Sunovion), Anacor Pharmaceuticals (acquired by Pfizer) and Agile Therapeutics (NASDAQ: AGRX).
Before joining Care Capital, Lorenzo conducted pre- and post-doctoral research in the Department of Cell Biology at Yale University and at the Max-Planck-Institute for Brain Research in Frankfurt am Main. His original research work was published in leading peer-reviewed scientific journals such as Nature, Cell and Neuron.
Lorenzo received a Laurea in Chemistry, summa cum laude, from the University of Padova, Italy; a Ph.D. in Biochemistry from the Max-Planck-Institute for Brain Research in Frankfurt am Main, Germany; and an M.B.A. with honors from The Wharton School of the University of Pennsylvania.
Linda C. Hogan
Linda brings over 30 years of experience in the health care industry, including biotech, venture capital, advisory services, and large pharma. Linda has focused primarily in the areas of product positioning, business strategy and corporate development.
She was most recently an officer and Vice President of Business Development and Strategy for CoLucid Pharmaceuticals, prior to its acquisition by Eli Lilly.  As Executive in Residence at Care Capital, a venture capital firm, Linda sourced and evaluated potential investment opportunities, assisting with the startup of several portfolio companies. In 2006, she formed LLH Associates, LLC, a consulting firm which provides business development and strategic transaction support to clients. During her 20 years with Aventis and its predecessor companies, Linda served in various roles of increasing responsibility in diverse functional areas, becoming Vice President, Global Business Development for Aventis.
Prior to joining the pharmaceutical industry, Linda was Assistant Professor of Pharmacy Practice and Director of Drug Information Services for the University of Kansas School of Pharmacy and Kansas University Medical Center. Linda continued as Adjunct Associate Professor Pharmacy Practice and served on the KU School of Pharmacy Advisory Council.
Professional awards include the TWIN (Tribute to Women in Industry) Award and the Donald E. Francke Award from the Drug Information Association.  Linda received BS and MS degrees in Pharmacy and Hospital Pharmacy from the University of Kansas and an MBA from Rockhurst College.
Linda is a Life Sciences Council Member of Springboard Enterprises and active with the Licensing Executives Society.
Neil H. Shusterman, MD
Dr. Neil H. Shusterman is the Chief Medical Officer at Palladio Biosciences. Neil is board certified in internal medicine and nephrology and is a highly experienced drug developer. During his pharmaceutical industry career of over 29 years holding senior senior leadership positions in large, medium, and small companies, Neil contributed to the development or approval of numerous drugs across multiple therapeutic areas, including argatroban injection, Aveed®, Bystolic®, Combunox™, Coreg, Corlopam™, Savella®, Teveten®, Vraylar™, and Xiaflex®. When approved, Coreg was the first new drug approved for heart failure in over 10 years and, in a paradigm shift, established beta blockade as the standard of care for heart failure therapy.
Prior to joining Palladio Biosciences, Neil worked at Endo Pharmaceuticals Inc., where he was the Chief Medical Officer with responsibility for 5 departments – Clinical Development and Operations, Medical Affairs, Drug Safety, Biometrics, and Scientific Communications; at Forest Laboratories, Inc., where he was Senior Vice President of Clinical Development at Forest Research Institute with responsibilities for Phase II – IV clinical development for five therapeutic areas – Cardiovascular, Pulmonary, Gastrointestinal/Metabolism, Psychiatry, and Neurology; and at SmithKline Beecham (subsequently GlaxoSmithKline), where he advanced to Vice President, Cardiovascular Therapeutic Area, North American Medical Affairs, Research and Development with worldwide responsibilities for all Phase II – IV cardiovascular drug development. During his tenure at SmithKline Beecham, Neil led the worldwide pivotal efficacy studies and regulatory filing for Coreg (carvedilol), the first beta-blocker approved for the treatment of chronic heart failure (CHF). That approval led to a paradigm-shift in the treatment of CHF, resulting in reduced morbidity and mortality in this devastating condition.  In addition, Neil led several large cardiovascular morbidity and mortality studies that recruited 20,000 patients combined at hundreds of sites on 3 continents.  
Before joining the pharmaceutical industry, Neil practiced nephrology at the University of Pennsylvania in Philadelphia, PA where he was Assistant Professor of Medicine and directed a large outpatient dialysis program. Neil has published and presented widely on topics in renal medicine, cardiovascular therapeutics, and drug development. He earned his undergraduate degree from the Pennsylvania State University and his M.D. from Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA.
Board of Directors
Sanford (Sandy) Zweifach

Sandy is the Chairman of the Board of Directors of Palladio Biosciences. 

Sandy brings to Palladio over 25 years’ experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising. He is the Co-Founder and Chief Executive Officer of Nuvelution Pharma, Inc.  Previously, Mr. Zweifach was the Co-founder and CEO of Ascendancy Healthcare, Inc.  He has also been a Partner at Reedland Capital Partners, CEO of Pathways Diagnostics, Managing Director and CFO of Bay City Capital, and President and CFO of Epoch Biosciences, which was acquired by Nanogen.

Sandy currently serves as the Chair of IMIDomics SL and Non-Executive Board Member of Compugen, Inc. (NASDAQ: CGEN) and Realm Therapeutics, Inc.   He received his BA in Biology from UC San Diego and an MS in Human Physiology from UC Davis.

Michèle Ollier, MD
Michèle is a Partner and co-founder of Medicxi, a leading international investment firm focused on life sciences. Prior to co-founding Medicxi, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time she invested and continues to serve on the boards of a number of Index Life Sciences portfolio companies including Epsilon 3 Bio, Minerva Neuroscience (NASDAQ: NERV), LinguaFlex, Gadeta, and Human Antibody Factory. She was also a Director at OncoEthix (sold to Merck Pharmaceuticals) and Aegerion (NASDAQ: AEGR).  Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/Gencell/Aventis International and Serono International.
Michèle currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN) and sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord.
Michèle completed her medical studies in France at Paris Ouest University.
Jonathan Edwards, Ph.D.
Jon is a Partner at Medicxi, a leading international investment firm focused on life sciences. Prior to joining Medicxi, Jon worked at Index Ventures in Geneva as an Associate for two years. Before that, he worked as a life science strategy consultant at ClearView Healthcare Partners in Boston. He currently serves on the board of directors of UltraHuman Limited and is an observer on the board of directors for Capella Bioscience, Apcintex, and Impact Biomedicines.
Jon obtained his PhD in biochemistry and biophysics from UNC Chapel Hill and also conducted postdoctoral research at MIT, where he is an affiliate in the department of biological engineering.
Frank Condella
Frank brings to Palladio Biosciences over 30 years’ experience in senior executive roles in the pharmaceutical industry. In addition to serving on the Board of Trustees of the PKD Foundation for several years, he most recently was President, Chief Executive Officer and a Director of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP), a position he held from 2009 until 2016. Previously, he was Chief Executive Officer of Skyepharma plc, President of European operations at IVAX, Chief Executive Officer of Faulding Pharmaceuticals, Vice President of the specialty care products business at Roche and Vice President and General Manager of the Lederle unit of American Home Products (Pfizer). He currently is Vice Chairman of Vectura Group plc and a Board Director of Juniper Pharmaceuticals. Previously he has served as Chairman of SkyePharma plc, and as an independent Director of Prosonix ltd and Fulcrum Pharma plc.
Mr. Condella earned an MBA from the D’Amore-McKim School of Business and a BS in Pharmacy from Bouvé College of Health Sciences at Northeastern University.